Opendata, web and dolomites

GLADIATOR SIGNED

Next-generation theranostics of brain pathologies with autonomous externally controllable nanonetworks: a trans-disciplinary approach with bio-nanodevice interfaces

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLADIATOR project word cloud

Explore the words cloud of the GLADIATOR project. It provides you a very rough idea of what is the project "GLADIATOR" about.

grim    cells    tumour    designed    bridging    conceptual    therapy    interventions    delivering    reprogramming    communications    supra    autologous    biological    vanguard    external    cancer    complete    time    evolution    hybrid    externally    recurrence    demand    nanonetworks    prognosis    disorders    diagnostics    optoelectronic    channels    micro    generate    pathologies    engineering    network    shift    coupled    wireless    host    inscs    progress    glioblastoma    interfering    insc    electronic    rationally    mirnas    cell    nanomachines    drastic    despite    discipline    nanotechnology    organoids    stimulation    emergence    appropriate    ict    consisting    therapeutic    intervention    environment    brain    multiforme    bio    societal    gladiator    exosomal    establishes    nanomachine    sensors    proof    promises    engineered    sciences    transforming    communication    life    release    tumours    neural    nanonetwork    cellular    breakthrough    components    oncology    things    internet    paradigm    spatiotemporal    malignancies    framework    burgeoning    clinically    applicable    sub    revolutionary    radiofrequency    nano    ecmc    detrimental    anticipated    radical    ushering    theranostic    therapeuticdiagnostic    monitor    solution    building    first    autonomously    autonomous    faceted    underlying    molecular    industry    socioeconomic    implantable    platform    prototype    stem    renewal    vision    fluorescent    interface   

Project "GLADIATOR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF CYPRUS 

Organization address
address: KALLIPOLEOS STREET 75
city: NICOSIA
postcode: 1678
website: www.ucy.ac.cy

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Cyprus [CY]
 Total cost 6˙122˙255 €
 EC max contribution 5˙982˙255 € (98%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF CYPRUS CY (NICOSIA) coordinator 953˙125.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 1˙758˙103.00
3    E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD CY (LEFKOSIA) participant 1˙111˙540.00
4    OULUN YLIOPISTO FI (OULU) participant 950˙535.00
5    NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU NO (TRONDHEIM) participant 787˙076.00
6    WATERFORD INSTITUTE OF TECHNOLOGY IE (Waterford) participant 421˙875.00
7    OSAKA UNIVERSITY JP (OSAKA) participant 0.00

Map

 Project objective

Brain pathologies are highly complex disorders. Despite recent progress, their prognosis is grim, defining a high societal challenge. Bridging life sciences, bio-nanotechnology, engineering and ICT, GLADIATOR promises a vanguard and comprehensive theranostic (therapeuticdiagnostic) solution for brain malignancies. Through a multi-faceted breakthrough, GLADIATOR will provide, for the first time, a working prototype of a complete, autonomous and clinically applicable, nanonetwork-based, Molecular Communications system based on the conceptual framework of Externally Controllable Molecular Communications (ECMC). Using Glioblastoma Multiforme tumours, the most detrimental brain pathologies, as a proof-of-concept case, GLADIATOR will implement a platform of cell-based and electronic components. Implantable autologous organoids of engineered neural stem cells (iNSCs) will release rationally designed exosomal bio-nanomachines, delivering reprogramming (therapeutic) miRNAs and building nanonetworks. Interfering with the underlying biological environment, the nanonetworks will define a revolutionary intervention. A hybrid bio-electronic interface, consisting of coupled external and implantable devices, will enable communication channels with host-derived fluorescent bio-nanomachines via micro-optoelectronic sensors. The cellular, sub-cellular and electronic components will be integrated into a wireless ECMC network. This system will autonomously monitor the spatiotemporal tumour evolution and recurrence and generate, on demand, appropriate reprogramming interventions, by radiofrequency stimulation of iNSC renewal. A paradigm shift in Oncology Research is anticipated via the supra-discipline of “bio-nanomachine diagnostics”. GLADIATOR establishes a radical long-term vision leading to a drastic change in cancer therapy, also ushering the emergence of the ECMC field and transforming the burgeoning industry of Internet of Nano-bio-things, with high socioeconomic impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLADIATOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLADIATOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FRINGE (2019)

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Read More  

SOLQC (2019)

Synthetic Oligonucleotide Quality Control Software

Read More  

BRIEFING (2018)

Bridging the FET Innovation Gap

Read More